Patents by Inventor Wulf Otto BOECHER

Wulf Otto BOECHER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF ANTI-IL-36R ANTIBODIES FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20240018232
    Abstract: The present invention relates to the treatment of inflammatory bowel disease (IBD) with anti-IL36R antibodies.
    Type: Application
    Filed: August 2, 2023
    Publication date: January 18, 2024
    Inventors: Wulf Otto BOECHER, Janine LAMAR, Steven John PADULA
  • ANTI IL-36R ANTIBODIES COMBINATION THERAPY
    Publication number: 20230044739
    Abstract: The present invention relates to anti-IL-36R binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: September 7, 2022
    Publication date: February 9, 2023
    Inventors: Wulf Otto BOECHER, Steven John PADULA, Christian THOMA
  • USE OF ANTI-IL-36R ANTIBODIES FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20210061901
    Abstract: The present invention relates to the treatment of inflammatory bowel disease (IBD) with anti-IL36R antibodies.
    Type: Application
    Filed: November 12, 2020
    Publication date: March 4, 2021
    Inventors: Wulf Otto BOECHER, Janine LAMAR, Steven John PADULA
  • METHODS OF TREATING DISEASES
    Publication number: 20200299378
    Abstract: This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: December 13, 2019
    Publication date: September 24, 2020
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Patrick BAUM, Wulf Otto BOECHER, Annette Bettina GALLER, Bojan LALOVIC, Sudha VISVANATHAN
  • USE OF ANTI-IL-36R ANTIBODIES FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20190284273
    Abstract: The present invention relates to the treatment of inflammatory bowel disease (IBD) with anti-IL36R antibodies.
    Type: Application
    Filed: March 8, 2019
    Publication date: September 19, 2019
    Inventors: Wulf Otto BOECHER, Janine LAMAR, Steven John PADULA
  • ANTI IL-36R ANTIBODIES COMBINATION THERAPY
    Publication number: 20180273627
    Abstract: The present invention relates to anti-IL-36R binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: March 26, 2018
    Publication date: September 27, 2018
    Inventors: Wulf Otto BOECHER, Steven John PADULA, Christian THOMA
  • METHODS OF TREATING DISEASES
    Publication number: 20180105588
    Abstract: This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: October 11, 2017
    Publication date: April 19, 2018
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Patrick Baum, Wulf Otto Boecher, Annette Bettina Galler, Bojan Lalovic, Sudha Visvanathan
  • METHODS OF TREATING INFLAMMATORY DISEASES
    Publication number: 20170081402
    Abstract: This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: September 15, 2016
    Publication date: March 23, 2017
    Inventors: Wulf Otto BOECHER, Annette Bettina GALLER, Bojan LALOVIC, Steven John PADULA, Paul SCHOLL, Sudha VISVANATHAN
  • COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE SUB-POPULATION
    Publication number: 20150147295
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in patients having genetic variations located near the IL28B gene, including SNP rs12979860 with a non-CC genotype and SNP rs8099917 with a non-TT genotype.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 28, 2015
    Inventors: Wulf Otto BOECHER, Gerhard NEHMIZ, Wiebke SAUTER, Gerhard G. STEINMANN, Heike ZIMDAHL-GELLING
  • COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE SUB-POPULATION
    Publication number: 20140271544
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in patients having genetic variations located near the IL28B gene, including SNP rs12979860 with a non-CC genotype and SNP rs8099917 with a non-TT genotype.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 18, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Wulf Otto BOECHER, Gerhard NEHMIZ, Wiebke SAUTER, Gerhard G. STEINMANN, Heike ZIMDAHL-GELLING
  • COMBINATION THERAPY FOR TREATING HCV INFECTION
    Publication number: 20120135949
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally (c) ribavirin, and methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.
    Type: Application
    Filed: September 23, 2011
    Publication date: May 31, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Wulf Otto BOECHER, Carla HAEFNER, George KUKOLJ